An Illustrated Guide to the USPTO’s New Memo on Method of Treatment Claims

June 29, 2018

Choose Your Weapon: Senate Amendment Pits ANDA/BPCIA Pathway Against Post-Grant Proceedings

June 26, 2018

Part 2 of 2: Supreme Court and Inter Partes Review

April 30, 2018

Part 1 of 2: Supreme Court and Inter Partes Review

April 30, 2018

Now Available! Seyfarth Shaw’s BioLoquitur Bulletin: Drugs Available in 2018 for Generic Competition

April 5, 2018

“Rigged” Pricing, Contracting and Rebate “Schemes,” and Drug Pricing “Shell Games:” FDA Commissioner Scott Gottlieb Lets Loose on the U.S. Biosimilar Market While Offering Peek at New Policies

March 19, 2018

Webinar: Biosimilar Litigation and Your BPCIA Compliance: Key Strategies In Light of AbbVie v. Boehringer

February 20, 2018

Now Available! Seyfarth Shaw’s Hatch-Waxman and Biosimilars Litigation: 2017 Year-in-Review

February 8, 2018

“Tax Cut and Jobs Act” H.R. 1 Passes House Of Representatives: Provisions To Watch

November 20, 2017

Sandoz v. Amgen: The Latest in Biosimilar “Dances”

June 28, 2017